Immunome Inc. (NASDAQ: IMNM) Chief Business Officer Horn Kinney completed a transaction involving the sale of 1,092 shares of common stock on July 7, 2026. The total value of this sale was recorded at $27,300, with each share transacted at a price of $25.00. This disposition of shares occurred shortly after Kinney exercised employee stock options to acquire an identical number of shares. The acquisition cost for these options was $14,108, calculated at a price of $12.92 per share. Following this sequence of events, Kinney no longer holds any direct shares of Immunome common stock, though the executive retains a substantial position of 128,908 employee stock options. The vesting schedule for these options dictated that 25% vested on August 9, 2025, with the remaining balance vesting on a monthly basis over the subsequent three years.
The sale was conducted in accordance with a Rule 10b5-1 trading plan that Kinney adopted on March 30, 2026. This structured approach to liquidity is designed to facilitate transactions in compliance with securities regulations. The transaction comes against a backdrop of significant price appreciation for Immunome, which has delivered a 172% return over the past year. As of the transaction date, the stock was trading at $24.17. Market analysis from InvestingPro suggests that the current valuation may be elevated relative to the company's fair value. Despite this perspective, analyst consensus remains optimistic, with price targets ranging from $30 to $40 per share.
Concurrent with the executive transaction, Immunome announced that the U.S. Food and Drug Administration has accepted its New Drug Application for varegacestat. This regulatory milestone pertains to the development of a treatment for desmoid tumors. The application is substantiated by clinical data from the Phase 3 RINGSIDE trial. The results from this trial demonstrated an 84% reduction in the risk of disease progression when compared to a placebo. This positive clinical outcome has prompted H.C. Wainwright to reiterate a Buy rating for Immunome, maintaining a price target of $40. Furthermore, Truist Securities has raised its price target on the stock to $37, citing the drug's robust efficacy and safety profile.
In addition to the regulatory progress, Immunome has advanced its clinical pipeline. The company announced the dosing of its first patient in a Phase 1 trial for IM-1617. This candidate is an antibody-drug conjugate designed for the treatment of solid tumors. The trial is structured to evaluate the safety, tolerability, and preliminary anti-tumor activity of the treatment. Immunome also presented detailed results from the Phase 3 trial at the American Society of Clinical Oncology Annual Meeting. These developments underscore the company's ongoing efforts in cancer treatment research and development. The stock has shown recent volatility, closing at $24.17 with a gain of $0.14, while after-hours trading saw a slight decline to $24.08.